Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis.

Br J Cancer · 2013 · PMC3553519 · PMID 23175147

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

marginal significanceP =0.06so close (0.05 < p ≤ 0.1)

No statistically significant survival benefit was observed from the comparison of the regimens containing platinum, taxane, or both to the chemotherapies with agents other than platinums or taxanes, except for the marginal significance of regimens containing both platinums and taxanes for a median survival time of 2.02 months ( P =0.06).

also in 3,086 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.